Dexcom director granted 5,565 RSUs

Ashley Euan A. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Ashley Euan A. reported acquisition or exercise transactions in this Form 4 filing.

Dexcom Inc. director Euan A. Ashley received an equity grant of 5,565 restricted stock units (RSUs) on May 28, 2026. The award carries no purchase price and is structured as stock-based compensation, not an open-market share purchase.

According to the terms, 100% of this RSU award will vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. After this grant, Ashley holds 12,731 unvested RSUs in total, including 7,166 RSUs granted on October 24, 2025 that are scheduled to vest in tranches through October 24, 2028.

Insider Trade Summary

Grant/Award: 5,565 shares

Grant/Award 1 txn

Insider Ashley Euan A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,565	$0.00	$0.00

Holdings After Transaction: Common Stock — 12,731 shares (Direct)

Footnotes (2)

1. F1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.
2. F2. Included in this number are 12,731 unvested restricted stock units, 5,565 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 7,166 of which were granted on October 24, 2025 and shall vest through October 24, 2028.

Key Figures

RSUs granted: 5,565 units Grant price per RSU: $0.00 per unit Total unvested RSUs after grant: 12,731 units +2 more

5 metrics

RSUs granted 5,565 units Common Stock RSU award on May 28, 2026

Grant price per RSU $0.00 per unit Reported transaction price per share

Total unvested RSUs after grant 12,731 units Holdings following May 28, 2026 award

New RSU vesting date Earlier of one year from May 28, 2026 or 2027 annual meeting Vesting trigger for 5,565-unit award

Prior RSU grant 7,166 units Granted on October 24, 2025; vesting through October 24, 2028

Key Terms

restricted stock unit, RSU Award, Annual Meeting of Stockholders, contingent right

4 terms

restricted stock unit financial

"Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU Award financial

"The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary"

Annual Meeting of Stockholders financial

"will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"

contingent right financial

"restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dexcom (DXCM) director Euan A. Ashley report in this Form 4?

Director Euan A. Ashley reported receiving a grant of 5,565 restricted stock units on May 28, 2026. These RSUs are stock-based compensation with no purchase price, increasing his total unvested RSU holdings to 12,731 after the grant.

How do the new Dexcom (DXCM) RSUs for Euan A. Ashley vest?

The 5,565 RSUs granted to Euan A. Ashley vest 100% on the earlier of the one-year anniversary of the May 28, 2026 grant date or DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Vesting must occur before shares of common stock are delivered.

What is Euan A. Ashley’s total Dexcom (DXCM) RSU position after this grant?

Following the May 28, 2026 grant, Euan A. Ashley holds 12,731 unvested restricted stock units. This total includes 5,565 RSUs granted on May 28, 2026 and 7,166 RSUs granted on October 24, 2025 that are scheduled to vest through October 24, 2028.

Does Euan A. Ashley pay a price for the new Dexcom (DXCM) RSUs?

The 5,565 RSUs granted to Euan A. Ashley have a reported per-share price of $0.00. This indicates they are compensation-based awards rather than open-market purchases, with each vested unit settling into one share of DexCom, Inc. common stock.

What earlier Dexcom (DXCM) RSU award to Euan A. Ashley is mentioned?

The filing notes an earlier grant of 7,166 restricted stock units to Euan A. Ashley on October 24, 2025. Those RSUs are scheduled to vest over time, with vesting continuing through October 24, 2028, subject to the award’s terms and conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 05:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ashley Euan A.

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		5,565(1)	A	$0	12,731(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

2. Included in this number are 12,731 unvested restricted stock units, 5,565 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 7,166 of which were granted on October 24, 2025 and shall vest through October 24, 2028.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Dr. Euan Ashley	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)